Bristol-Myers Squibb Company BMY
Starboard urges BMY shareholders to reject the $91B Celgene acquisition — it imports a massive REVLIMID patent cliff and was rushed through without exploring standalone turnaround or a sale of Bristol-Myers.
Thesis
Bristol-Myers Squibb has chronically underperformed pharma peers under CEO Giovanni Caforio, yet is now attempting a 'bet the company' $91B acquisition of Celgene that Starboard Value argues destroys rather than creates shareholder value. The Celgene deal imports one of the largest patent cliffs in pharma history — REVLIMID alone generates over 60% of Celgene revenues and faces generic competition starting 2022, with management itself projecting a ~90% revenue decline by 2026. Bristol-Myers conducted only about two weeks of full data-room diligence on roughly 30 highly technical Celgene pipeline products before committing, and never explored strategic alternatives including a potential sale of BMY. Starboard urges shareholders to vote down the share issuance at the April 12 Special Meeting, has filed a books-and-records demand, and has nominated a slate of directors for the 2019 Annual Meeting to pursue either a focused standalone strategy or a sale of the Company.
SCQA
Bristol-Myers Squibb is a leading immuno-oncology pharmaceutical company that has persistently underperformed peers on total shareholder return, EBITDA margins, and P/E multiple throughout CEO Giovanni Caforio's tenure.
Management has announced a 'bet the company' $91B acquisition of Celgene, which imports a massive small-molecule REVLIMID patent cliff, relies on an unproven pipeline, and was diligenced in just two weeks with no exploration of alternatives.
Shareholders should vote against the Celgene share issuance at the April 12 Special Meeting; Starboard has nominated a director slate for the 2019 Annual Meeting to hold the Board accountable and force exploration of strategic alternatives.
Blocking the deal preserves a more profitable standalone pathway with margin expansion potential, or opens a sale of Bristol-Myers — a premier oncology asset — at a substantial premium to the depressed current price.
The three reasons
- 1
Bristol-Myers is buying one of the largest patent cliffs in pharma history via REVLIMID
- 2
Only two weeks of full data-room diligence preceded the $91B 'bet the company' deal
- 3
BMY has underperformed peers by ~40% over 5 years under CEO Caforio
Primary demands
- Vote against the share issuance related to the proposed Celgene acquisition at the April 12, 2019 Special Meeting
- Elect Starboard's slate of director nominees at the 2019 Annual Meeting to hold the Board accountable
- Honor the books-and-records demand under Delaware law to investigate the diligence process behind the Celgene deal
- Explore all strategic alternatives, including a standalone refocusing or a sale of Bristol-Myers
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- LIPITOR, CRESTOR, PLAVIX, GLEEVEC small-molecule revenue cliffs post-LOE
- EPOGEN, NEULASTA, REMICADE biologics demonstrating durable post-LOE revenue
- Celgene's GED-0301 Crohn's termination and ozanimod refusal-to-file as prior over-promising
- YESCARTA and KYMRIAH declining CAR-T revenue estimates
Notable slides (5)
Notes
Opening letter of Starboard's 2019 BMY/Celgene campaign — positions Starboard as defensive activist opposing a transformative deal rather than demanding operational change at the target. Primary rhetorical moves: (1) Caforio CEO-tenure TSR table right up front, (2) small-molecule vs. biologics patent-cliff curves to argue REVLIMID is uniquely exposed, (3) timeline of Celgene executive quotes that were contradicted within months (GED-0301, ozanimod, JCAR017) used as proxy for Celgene pipeline credibility, (4) annotated BMY stock chart tying activist involvement, CHECKMATE failures, and merger timing to imply defensive motivation. Jeffrey C. Smith signs off on page 16; no specific ownership percentage disclosed. Campaign outcome: Starboard withdrew opposition and the Celgene acquisition closed November 2019.